An Min Sung, Baik HyungJoo, Oh Se Hui, Park Yo-Han, Seo Sang Hyuk, Kim Kwang Hee, Hong Kwan Hee, Bae Ki Beom
Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University, Busan, South Korea.
ANZ J Surg. 2018 Oct;88(10):E698-E702. doi: 10.1111/ans.14493. Epub 2018 Jun 12.
Complete mesocolic excision (CME) has been proposed for colon cancer to improve oncological outcomes. The risks and benefits of laparoscopic CME have not been examined fully. We compared short- and long-term outcomes of CME with a conventional mesocolic excision (non-CME) in laparoscopic right hemicolectomy (RHC) for right-sided colon cancer.
In total, 115 patients who underwent laparoscopic RHC with stage I-III right-sided colon cancer at Busan Paik Hospital from August 2007 to October 2011 were enrolled in this case-control study. Three trained colorectal surgeons reviewed videos of the surgeries; patients were divided into two groups: those who underwent a CME (CME group, n = 34) and those who underwent a conventional mesocolic excision (non-CME group, n = 81).
There was no significant difference between the CME and non-CME groups in operative time, post-operative complications, or hospital stay. However, the CME group had more lymph nodes harvested (P < 0.001) and lower blood loss (P = 0.016) versus the non-CME group. There was no difference in 5-year disease-free survival rate between the groups, but 5-year overall survival rate was 100% in the CME group and 89.49% in the non-CME group (P < 0.05).
Laparoscopic RHC with CME is safe and associated with better 5-year overall survival rate than non-CME for patients with stage I-III right-sided colon cancer. Implementation of CME surgery might improve oncological outcomes for patients with right-sided colon cancer.
全结肠系膜切除术(CME)已被提出用于结肠癌以改善肿瘤学结局。腹腔镜CME的风险和益处尚未得到充分研究。我们比较了腹腔镜右半结肠切除术(RHC)治疗右侧结肠癌时,CME与传统结肠系膜切除术(非CME)的短期和长期结局。
2007年8月至2011年10月在釜山白医院接受腹腔镜RHC治疗I-III期右侧结肠癌的115例患者纳入本病例对照研究。三位经过培训的结直肠外科医生查看手术视频;患者分为两组:接受CME的患者(CME组,n = 34)和接受传统结肠系膜切除术的患者(非CME组,n = 81)。
CME组和非CME组在手术时间、术后并发症或住院时间方面无显著差异。然而,与非CME组相比,CME组切除的淋巴结更多(P < 0.001),失血量更低(P = 0.016)。两组间5年无病生存率无差异,但CME组5年总生存率为100%,非CME组为89.49%(P < 0.05)。
对于I-III期右侧结肠癌患者,腹腔镜RHC联合CME是安全的,且5年总生存率优于非CME。实施CME手术可能改善右侧结肠癌患者的肿瘤学结局。